Business Description
Curis Inc
NAICS : 325414
SIC : 2836
Description
Curis Inc is a biotechnology company that develops and commercializes innovative drugs and therapies in the immuno-oncology and precision oncology therapeutic areas. The company targets solid tumors, diffuse large B-cell lymphoma, advanced solid tumors or lymphomas, hematological cancers, and others. Its pipeline products include Fimepinostat, CA-170, CA-4948, CA-327, and Erivedge.
Financial Strength
4/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Cash-To-Debt | 23.49 | |||||
| Equity-to-Asset | 0.45 | |||||
| Debt-to-Equity | 0.08 | |||||
| Debt-to-EBITDA | -0.08 | |||||
| Piotroski F-Score | 4/9 | |||||
| Altman Z-Score | -12.77 | |||||
| Beneish M-Score | -3.37 | |||||
| WACC vs ROIC | ||||||
Growth Rank
3/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Revenue Growth Rate | -28.3 | |||||
| 3-Year EBITDA Growth Rate | 19.7 | |||||
| 3-Year EPS without NRI Growth Rate | 20.1 | |||||
| 3-Year FCF Growth Rate | 23.3 | |||||
| Future 3-5Y Total Revenue Growth Rate Industry Rank | 0.57 |
Momentum Rank
10/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 5-Day RSI | 38.41 | |||||
| 9-Day RSI | 43.22 | |||||
| 14-Day RSI | 46.23 | |||||
| 6-1 Month Momentum % | 6.33 | |||||
| 12-1 Month Momentum % | -81.95 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Current Ratio | 7.69 | |||||
| Quick Ratio | 7.69 | |||||
| Cash Ratio | 7.18 | |||||
| Days Sales Outstanding | 94.84 | |||||
| Days Payable | 5420.94 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Average Share Buyback Ratio | -40.3 |
Profitability Rank
2/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Gross Margin % | 96.71 | |||||
| Operating Margin % | -531.86 | |||||
| Net Margin % | -566.41 | |||||
| ROE % | -76.1 | |||||
| ROA % | -40.56 | |||||
| ROIC % | -194.01 | |||||
| ROC (Joel Greenblatt) % | -944.72 | |||||
| ROCE % | -40.95 |
GF Value Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| PS Ratio | 7.15 | |||||
| PB Ratio | 1.38 | |||||
| Price-to-Tangible-Book | 1.63 | |||||
| EV-to-EBIT | 0.33 | |||||
| EV-to-EBITDA | 0.33 | |||||
| EV-to-Revenue | -1.73 | |||||
| EV-to-Forward-Revenue | 0.01 | |||||
| EV-to-FCF | 0.36 | |||||
| Price-to-Median-PS-Value | 0.46 | |||||
| Price-to-Net-Current-Asset-Value | 2 | |||||
| Price-to-Net-Cash | 2.42 | |||||
| Earnings Yield (Greenblatt) % | 303.03 |
Guru Trades
See DetailsInsider Trades
See DetailsGurus Latest Trades with NAS:CRIS
Peter Lynch Chart
Performance
Dividend
Log
Annualized Return %
Total Annual Return %
Executives
Analyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil $) | 10.41 | ||
| EPS (TTM) ($) | -0.64 | ||
| Beta | 2.66 | ||
| Volatility % | 84.71 | ||
| 14-Day RSI | 46.23 | ||
| 14-Day ATR ($) | 0.05554 | ||
| 20-Day SMA ($) | 0.82616 | ||
| 12-1 Month Momentum % | -81.95 | ||
| 52-Week Range ($) | 0.68 - 5.27 | ||
| Shares Outstanding (Mil) | 96.4 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 4 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
Curis Inc Filings
| Document | Form | Filing Date | ||
|---|---|---|---|---|
| No Filing Data | ||||
Curis Inc Analysis
Share your researchHeadlines
See More
No news.